ArticleAsian Pacific journal of cancer prevention : APJCP2026
Prediction of Outcomes of Brain Irradiation in Correlation with Molecular Subtypes in Patients with Metastatic Breast Cancer.
Article in Asian Pacific journal of cancer prevention : APJCP, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBrain metastases (BM) are a major complication in metastatic breast cancer, especially in HER2-positive and triple-negative subtypes. Despite advances in systemic therapy, BM remains associated with a poor prognosis and often requires radiotherapy. This study evaluates the outcomes of brain irradiation across subtypes and proposes a prognostic scoring system to guide treatment.
methodsThis retrospective study analyzed data from 348 breast cancer patients with BM to develop a prognostic scoring system for radiotherapy decisions. The data included molecular subtypes, number of brain lesions, and survival outcomes. Kaplan-Meier and Cox proportional hazards models were used to identify prognostic factors. The scoring system, based on the significance of predictors, was compared with physician-selected radiotherapy techniques to assess its potential for optimizing care.
resultsLuminal breast cancer was most prevalent (42.6%), followed by HER2-positive and triple-negative (19% each). Median BM onset was 23 months; headache was the most common symptom (48%). HER2-positive and triple-negative patients developed metastases earlier than luminal and triple-positive (P=0.001). Survival was better for luminal and triple-positive, poorer for HER2-positive and triple-negative. Patients with fewer than five brain lesions had higher survival rates (P=0.001). The scoring system incorporated molecular subtype, lesion burden, and patient characteristics. Scores above 3.5 predicted worse survival, with higher scores strongly linked to poorer outcomes (P=0.001).
conclusionThis study identifies key prognostic factors influencing survival in breast cancer patients with BM and proposes a scoring system to guide radiotherapy decisions. Molecular subtypes, metastatic burden, and clinical characteristics significantly affect outcomes, with HER2-positive and triple-negative subtypes showing the poorest survival. The system provides a structured approach for treatment selection, though further validation is needed to ensure its accuracy and clinical utility in personalized radiotherapy planning.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.